Patrick Widhelm is Director, Clinical Delivery, where he serves as Executive Lead on Proxima’s Clinical studies and oversees end-to-end delivery of Phase I–IV clinical trials from study startup through execution and closeout. A senior clinical operations leader with over 17 years of experience delivering global Phase I–III clinical trials, Patrick brings deep expertise in oncology across solid tumors, hematologic malignancies, and cell and gene therapies. He is known for driving efficient trial execution, rescuing challenged studies, and translating development strategy into operational excellence. At Proxima, he ensures studies meet timeline, quality, and budget targets in compliance with ICH GCP, regulatory requirements, and applicable SOPs; serves as the primary point of escalation for sponsors; drives risk-based trial management; and leads the selection and oversight of trial vendors.
Patrick has led complex, high-budget programs on both the sponsor and CRO sides. As Senior Director, Clinical Operations and Project Management at ImmuneSensor Therapeutics, he directed global clinical operations for a pipeline of cGAS-STING autoimmune and oncology programs. His CRO leadership experience includes senior roles at Caidya (formerly Clinpace), Precision for Medicine, ICON plc, and Sarah Cannon Research Institute.
United States Air Force Academy: Management, BS
Harvard University, John F. Kennedy School of Government: Public Policy, MPP
Proxima Clinical
Director, Clinical Delivery
HGI Clinical (now Proxima Clinical)
Director, Clinical Delivery
Achieve Clinical Consulting
CEO and Founder
ImmuneSensor Therapeutics, Inc.
Senior Director, Clinical Operations and Project Management
Caidya (formerly Clinpace)
Senior Director, Clinical Development (promoted from Director)
Precision for Medicine
Project Director
ICON plc
Senior Project Manager, CAR-T Center of Excellence
Sarah Cannon Research Institute
Senior Project Manager
Sarah Cannon Research Institute
Portfolio Manager
Endeavor Clinical Trials / Independent Clinical Research, LLC
Chief Operating Officer
USAA Federal Savings Bank
Business Architect
United States Air Force
Space Launch Officer
Development Programs Supported:
STING agonist (IMSA101) in combination with radiotherapy and checkpoint inhibitors for oligometastatic and oligoprogressive solid tumor malignancies (two Phase II trials)
cGAS-STING pathway therapeutics for autoimmune diseases
Adoptive cellular therapies (CAR-T) for oncology indications (ICON CAR-T Center of Excellence; Caidya and Precision cell therapy portfolios)
Drug for uveal melanoma (global Phase I/II; 166 subjects at 30 sites)
Drugs for bladder cancer (Phase Ib randomized umbrella trial; 135 patients across six treatment arms in five US and EU countries)
Portfolio of 60+ Phase I/II/III solid tumor and hematologic malignancy trials spanning a wide range of drug types and mechanisms of action (Sarah Cannon Research Institute)
Site-level research in orthopedics, nephrology, pain management, vaccines, surgery, dermatology, and cardiovascular disease
Publications:
Ph II Clinical Trials to Evaluate Safety and Efficacy of IMSA101 + Radiotherapy + Checkpoint Inhibitors in Oligometastatic and Oligoprogressive Solid Tumor Malignancies. American Society of Clinical Oncology (ASCO) Annual Meeting, 2024.
Therapeutic Areas:
Oncology (Phase I, II, and III; solid tumors and hematologic malignancies); Cell and Gene Therapy (CGT); Autoimmune Diseases
Certifications:
Certified Professional (ACRP-CP), Association of Clinical Research Professionals
Lean Six Sigma Black Belt, Certification No. BB-000004


